Improved in Medical Technology

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that Vectibix((R)) (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with F...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

SAN DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first cli...

HCPC Calls for Greater Healthcare Savings Through Improved Adherence to Prescription Drug Regimens

FALLS CHURCH, Va., June 22 /PRNewswire-USNewswire/ -- With today's announcement that the Pharmaceutical Research and Manufacturers of America (PhRMA) has offered to voluntarily grant some $80 billion in discounts to Medicare beneficiaries over the next decade in an effort to reduce overall healthc...

Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables

Data from Phase II/III Study Presented at Heart Failure Congress 2009 Demonstrate Promising Safety and Efficacy Results for Relaxin SAN MATEO¿ Calif.¿ June 1 /PRNewswire/ -- Corthera Inc. today announced that the results and additional statistical analyses conducted from Pre-RELAX-AHF, the Phase...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at thr...

CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy

Non-adherent women up to six times more likely to experience a fracture WOONSOCKET, R.I., May 11 /PRNewswire/ -- Data released today by CVS Caremark (NYSE: CVS ) indicates that 87 percent of women 18 years and older with osteoporosis, who were taking a drug therapy to treat the disease, di...

Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples

Data Published in May Issue of Journal of Sexual Medicine INDIANAPOLIS, May 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced results from a double-blind, placebo-controlled study which showed that tadalafil 5 mg dose taken once daily was generally well-...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

GENEVA, Feb. 3 /PRNewswire/ -- -- The Six-Month Primary Efficacy Endpoint of the Study was met: Both Doses of Investigational Agent Safinamide Significantly Increased "ON" Time in Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease -- Secondary Efficacy Endpoi...

New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults

SAN FRANCISCO, Nov. 19 /PRNewswire/ -- Posit Science Corporation researcher, Dan Tinker, presented evidence at the Society for Neuroscience Annual Conference in Washington, DC this week indicating that cognitive training may benefit Baby Boomers. The computerized brain plasticity-based Brain Fitn...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

Data also found SYMBICORT opened airways in less than 15 minutes WILMINGTON, Del., Oct. 29 /PRNewswire-FirstCall/ -- Data presented today from two pivotal efficacy and safety trials, SHINE and SUN, demonstrated that SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol...

National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon

Study evaluates the efficacy of new device for detecting polyps that can be missed during colonoscopy ORLANDO, Fla., Oct. 7 /PRNewswire/ -- At the American College of Gastroenterology Annual Scientific Meeting in Orlando (ACG 2008), renowned gastroenterologist Douglas K. Re...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in th...

CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price

WOBURN, Mass., Aug. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the release of the Maestro(TM) EX In Vivo Imaging System. The new system incorporates CRi's state-of-the-art FLEX technology and becomes the entry-level instrument of choice for in vivo fluorescen...

Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery

SOUTH EASTON, Mass., June 24 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" and "the Company") today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) Grant (2R44GM079059-02) from the National Institutes of Health (NIH). The G...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

Data Suggest Role of Hemolysis in PNH-Related Fatigue Presentation at the European Hematology Association 13th Congress CHESHIRE, Conn., June 15 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab) therapy improved the often disabling fatigue experienced by patients with the rare blood...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

Patients Receiving Every Four-Week Subcutaneous Golimumab Also Experienced Improvements in Physical Function and Disease Activity PARIS, June 11 /PRNewswire/ -- Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNT...

Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-re...

Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss

Submitted to FDA for Stand-Alone Therapy in Q1 2008 SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced additional results from a study of patients with type 2 diabetes who were unable t...

Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function

TORONTO, June 1 /PRNewswire/ -- The final results of the Spare the Nephron (STN) study, a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil), showed the CellCept-based regimen in combination with sirolimus (SRL) is associated wit...

Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer

Analysis Reveals Overall Survival Could be Extended if Patients Receive the Most Effective Treatment Identified by ChemoFx CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific...

New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many strong acting pain medications have bothersome side effects. These can include nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead patients to discontinue treatment, adding additional comp...

Medivation's Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimer's Disease Patients Over One Year

- Cognitive Function Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients treated with the investigatio...

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

Additional Data Demonstrate Predictable, Extended Exposure with Sustained- Release Formulation CHICAGO, April 17 /PRNewswire/ -- Data from the first pivotal study of XP13512/GSK1838262, a sustained-release investigational compound to treat Restless Legs Syndrome (RLS), ...

Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance

- Activities of Daily Living Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients taking the investigationa...

MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients

Study Continues to Show Lasting Reductions in Mitral Regurgitation Across a Spectrum of Patients CHICAGO, April 1, 2008 /PRNewswire/ -- Percutaneous mitral repair using the MitraClip(R) device may successfully reduce mitral regurgitation (MR) in patients suffering from f...

CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model

Data Presented at annual American College of Cardiology (ACC) Scientific Sessions Demonstrates Further Potential of Company's Platform ECM(TM) Technology CHICAGO and ATLANTA, April 1, 2008 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company...

Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients

Year-end 2007 long-term follow-up data continues to be positive BETHESDA, Md., Feb. 20 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") today announced the most recent long-term follow-up data, as of year-end...

IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology

Children's Oncology Group Report Shows the Addition of L-MTP-PE to Chemotherapy Reduced the Risk of Death by 30% in Osteosarcoma Patients IRVINE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ) today announced the Journal of Clinical Oncology (JCO) has publishe...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

Study Shows that Long-Term Soliris Therapy Continued to Be Associated with Reductions in Thrombosis and Improvements in Fatigue, Quality of Life, and Anemia in PNH Patients Data Presented at the American Society of Hematology (ASH) Annual Meeting Po...

Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood

- Additional Data Show the Standard Treatment for Sickle Cell Disease is Widely Under-Prescribed in Some Populations - ATLANTA, Dec. 8 /PRNewswire-USNewswire/ -- New research to be presented at the 49th Annual Meeting of the American Society of Hematology in Atlanta, GA, will provide impor...

Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders

Kennedy Krieger Institute Research Confirms Parent and Physician Reports that Children with Autism Spectrum Disorders Exhibit Fewer Autistic-like Behaviors during Illness with Fever BALTIMORE, Dec. 3 /PRNewswire-USNewswire/ -- Over the past few decades, parents and clinicians have observed...

Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)

- Data presented at American College of Rheumatology Annual Congress - BOSTON, Nov. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA(R) (abatacept) improved dail...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

Golimumab Achieved Primary and Major Secondary Endpoints in the Largest Phase 3 Biologic Trial Completed to Date in Psoriatic Arthritis BOSTON, Nov. 7 /PRNewswire/ -- Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced ...

Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions

TAXUS ATLAS studies also reinforce deliverability of TAXUS(R) Liberte(R) drug-eluting stent in long lesions and small vessels NATICK, Mass. and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced nine-month data from the pivotal TA...

Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis

Three Subcutaneous Doses of Ustekinumab Resulted in Long-term PASI 75 Response and Marked Improvement in Quality of Life Measures According to Study Findings BUENOS AIRES, Argentina, Oct. 3 /PRNewswire/ -- The first reported findings from an international, Phase ...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

-- When compared to insulin glargine, exenatide offered added benefits of weight loss and improved beta-cell function when used with metformin -- AMSTERDAM, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) to...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

-- When compared to insulin glargine, exenatide offered added benefits of weight loss and improved beta-cell function when used with metformin -- AMSTERDAM, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) to...

Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial

Trial to be Stopped Early to Allow All Patients Access to Nexavar WAYNE, N.J. and EMERYVILLE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals (NYSE: BAY ) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a planned review by an independent data...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensives to Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findings from ECLIPSE**, the largest safety program comparing intravenous antihypertensive therapies, show that improved control of ...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

Three Oritavancin Studies Presented at ECCMID/ICC MUNICH, Germany, April 03, 2007 /PRNewswire/ -- Targanta Therapeutics today announced results from two studies showing the improved potency of oritavancin to stop bacterial growth in vitro when tested with a common wetting agent (polysorbate 80) an...